Treatment library
Preparing current medications, procedures, devices, and historical context.
This is a neutral treatment library, not a recommendation engine. It covers current medications, surgeries, devices, and major discontinued treatments readers still search so the category is easier to compare in one place.
Cost, dosing, coverage, and availability are editorial summaries for orientation. Verify anything material with a clinician, surgeon, or pharmacist before acting on it.
Appetite suppression through older serotonergic and stimulant pathways
The historical combination of fenfluramine and phentermine that became a cautionary landmark in weight-loss drug history after valvular-heart-disease concerns led to withdrawal of the fenfluramine component.
1990s combination use
Not applicable as a current treatment pathway.
Selective serotonin 2C receptor agonist
Lorcaserin’s branded obesity-drug era ended after the FDA requested market withdrawal because a safety clinical trial found an increased occurrence of cancer.
2012
Not applicable as a current treatment option.
Central norepinephrine and serotonin reuptake inhibition
Sibutramine’s obesity-drug story ended after cardiovascular safety concerns led the FDA to recommend against continued use and the product left the U.S. market.
1997
Not applicable as a current treatment option.
Historical temporary intragastric balloon
A swallowable gas-filled intragastric-balloon system that became one of the more distinctive balloon products in the U.S. balloon era. It is now mainly relevant as a historical balloon reference rather than a mainstream current pathway.
2016
Not a mainstream covered current option.